ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 13 of 42 for:    "Porphyria"

Panhematin for Prevention of Acute Attacks of Porphyria

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02922413
Recruitment Status : Recruiting
First Posted : October 4, 2016
Last Update Posted : July 17, 2018
Sponsor:
Information provided by (Responsible Party):
The University of Texas Medical Branch, Galveston

Brief Summary:

The purpose of this study is to determine if Panhematin is safe and effective for prevention of acute attacks of porphyria.

The study aims to provide high quality evidence for the use on hemin for prevention of acute attacks of porphyria. A separate study is in progress to evaluate the use of Panhematin for treatment of acute attacks of porphyria. Such studies have not been done previously for treating or preventing acute attacks with hemin. The lack of strong evidence for efficacy of hemin for treatment and prevention of attacks limits its availability for patients with acute porphyrias.


Condition or disease Intervention/treatment Phase
Acute Intermittent Porphyria Hereditary Coproporphyria Variegate Porphyria Biological: Hemin for injection Other: Placebo Phase 2

Detailed Description:

This is a double-blind, randomized, placebo-controlled, parallel group trial investigating the efficacy and safety of Panhematin™ for preventing acute attacks in at least 20 patients with well-documented acute porphyria (acute intermittent porphyria, hereditary coproporphyria or variegate porphyria). These patients will (1.) have had frequent attacks in the past, with symptoms such as abdominal, back and/or limb pain and diagnosed after exclusion of other causes, and (2.) be on hemin prophylaxis for prevention of frequent attacks. It is expected that patients will have had 6 or more attacks in one year before starting hemin prophylaxis. This would be considered justification for a preventive regimen of hemin on clinical grounds. A single double blind dose of Panhematin™ or placebo will be given. An interim analysis will be carried out after completion of 10 patients to assess progress and possibly adjust the sample size. The trial consists of the following:

  • A screening visit to determine eligibility and obtain informed consent
  • A treatment visit for administration of a double blind prophylactic dose of Panhematin™ or placebo
  • Follow up visit at 1, 2, 3, and 4 weeks to assess response to the infusion of Panhematin™ or placebo. These visits will be in person or by telephone.
  • Additional visits may be scheduled if needed, for example for treatment of symptoms.
  • Follow-up visits 3 and 6 months after the end of treatment either in person or by telephone Patients will have laboratory documentation of one of the acute porphyrias. Molecular documentation is also expected, although rarely a causative mutation cannot be detected. Upon entry into the study they will be given in a blinded fashion a single preventive dose of either Panhematin™ (4 mg/kg) or placebo. A recurrent attack within the next 1, 2, 3 and 4 weeks will represent treatment failures. Because at study entry most patients are expected to be on weekly prophylactic hemin treatment, and hemin is a short-acting drug, emphasis in the analysis will be on attacks occurring within 1 week after study treatment.

Any attacks that occur during the study will be treated according to standard of care, which may include Panhematin™, either at the study site or at the patient's usual treatment location.

It is intended that 20 patients will complete treatment with a single blinded dose and at least 4 weeks of follow up. A completed patient is one who meets all entrance criteria, has no exclusion criteria and completes the single dosing and at least one week of follow up, or is withdrawn because of an adverse event.


Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Safety and Efficacy of Panhematin™ for Prevention of Acute Attacks of Porphyria
Study Start Date : August 2015
Estimated Primary Completion Date : September 2020
Estimated Study Completion Date : September 2021


Arm Intervention/treatment
Experimental: Hemin for injection
A double blind dose single dose of Panhematin 4 mg/kg body weight reconstituted with 25% human albumin and infused over at least one hour.
Biological: Hemin for injection
A single dose of Panhematin 4 mg/kg body weight reconstituted with 25% human albumin infused intravenously over at least 1 hour.
Other Name: Hematin

Placebo Comparator: Placebo
A double blind dose of saline.
Other: Placebo
Saline infusion




Primary Outcome Measures :
  1. Occurance of an acute attack of porphyria after treatment [ Time Frame: 1-4 weeks ]
    To evaluate in 20 patients who are on a Panhematin™ prophylactic regimen whether a blinded dose of Panhematin™ is more effective than placebo in preventing an attack within the next 1-4 weeks. The emphasis will be placed on prevention of attacks in the next week.

  2. Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 [ Time Frame: 1-4 weeks ]
    To evaluate in 20 patients whether hemin reconstituted with 25% human albumin is as safe and well tolerated as placebo when administered in a blinded fashion. Safety parameters will include the frequency and severity of phlebitis, nausea, vomiting and coagulation abnormalities.


Secondary Outcome Measures :
  1. Effects on levels of porphobilinogen [ Time Frame: 1-4 weeks ]
    To evaluate the biochemical effects of Panhematin™ in patients treated with Panhematin™ to prevent attacks of acute porphyria by measuring urinary porphobilinogen and serum porphobilinogen. This will determine whether biochemical measurements are predictive of efficacy in preventing an attack.


Other Outcome Measures:
  1. Effects of age [ Time Frame: 1-4 weeks ]
    To evaluate effects of age, as an example of clinical features, on response to preventive administration of Panhematin™.

  2. Effects of the nature of the PBGD mutation [ Time Frame: 1-4 weeks ]
    To evaluate effects of the nature or the PBGD mutation on response to preventive Panhematin™

  3. Frequency of injection site complications [ Time Frame: 1-4 weeks ]
    To evaluate the use of Panhematin™ reconstituted with 25% human albumin in patients treated to prevent acute attacks of porphyria in terms of the frequency of injection site complications, which may include thrombosis or inflammation.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male or female aged 18 years
  2. Willing to provide written informed consent
  3. A diagnosis of acute intermittent porphyria, hereditary coproporphyria or variegate porphyria confirmed by the following criteria, which are based on the criteria for enrollment in the Longitudinal Study of the Porphyrias Consortium. For each type of porphyria, the inclusion criteria are based on 1) clinical features, 2) biochemical findings, as documented by laboratory reports (or copies) of porphyria-specific testing, and 3) molecular studies to identify a mutation in a porphyria-related gene. Equivocal biochemical measurements may require confirmatory testing. Testing for a disease-causing mutation must be attempted, but an identified mutation is not essential for enrollment, since it is known that a mutation cannot be found in a small fraction (<5%) of biochemically proven cases of porphyria.

Exclusion Criteria:

  1. Symptoms such as abdominal, back or limb pain are explained by another condition, as judged by the investigator
  2. Known or suspected allergy to Panhematin™ or related products
  3. A known or suspected allergy to human albumin
  4. Any disease or condition that the investigator judges would lead to an unacceptable risk to the patient or interfere with the successful collection of data for the trial
  5. Previous randomization in this trial

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02922413


Contacts
Contact: Karl E Anderson, MD 409-772-4661 kanderso@utmb.edu
Contact: Csilla Hallberg, MD 409-772-4661 ckhallbe@UTMB.EDU

Locations
United States, Texas
University of Texas Medical Branch Recruiting
Galveston, Texas, United States, 77555
Contact: Karl E Anderson, MD    409-772-4661    kanderso@utmb.edu   
Contact: Csilla Hallberg, MD    409-772-4661 ext 24661    ckhallbe@UTMB.EDU   
Sponsors and Collaborators
The University of Texas Medical Branch, Galveston

Responsible Party: The University of Texas Medical Branch, Galveston
ClinicalTrials.gov Identifier: NCT02922413     History of Changes
Other Study ID Numbers: 14-0188
First Posted: October 4, 2016    Key Record Dates
Last Update Posted: July 17, 2018
Last Verified: June 2018

Keywords provided by The University of Texas Medical Branch, Galveston:
Porphyria
Heme

Additional relevant MeSH terms:
Porphyrias
Porphyria, Erythropoietic
Porphyria, Acute Intermittent
Porphyria, Variegate
Porphyrias, Hepatic
Coproporphyria, Hereditary
Metabolic Diseases
Skin Diseases, Genetic
Genetic Diseases, Inborn
Skin Diseases
Liver Diseases
Digestive System Diseases